Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 6/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22619001 | 0.79 | PFKFB3 (0.41) | CA2PFKFB3ALDH1A1 | |
| SCHEMBL3176276 | 0.78 | KEAP1 (0.50) | PGRCA2PFKFB3ALDH1A1POLB | |
| SCHEMBL10100499 | 0.74 | KEAP1 (0.55) | EGFRTNNI3KCA2ALDH1A1POLB | |
| SCHEMBL10169497 | 0.74 | HTR6 (0.59) | ALOX12PGRCA2ALDH1A1POLB | |
| SCHEMBL15474323 | 0.71 | CA2 (0.61) | ALOX12PGRCA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13181439 | 0.71 | KDM1A (0.48) | EGFRTNNI3KALOX12PGRCA2 | |
| SCHEMBL14508412 | 0.71 | CA2 (0.55) | EGFRTNNI3KALOX12PGRCA2 | |
| SCHEMBL21348470 | 0.70 | SMN1; SMN2 (0.53) | CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL22220775 | 0.70 | CA2 (0.47) | EGFRTNNI3KALOX12CA2SMN1; SMN2 | |
| SCHEMBL27182647 | 0.70 | CA2 (0.50) | EGFRTNNI3KALOX12PGRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PRLHR, DRD2, AVPR2 | EGFR 1881/4885TNNI3K 3827/4885ALOX12 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.